Search results
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Benzinga via Yahoo Finance· 2 years agoThe European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharma's CAR...
Gilead to lay off staff at cell therapy unit Kite
BioPharma Dive via Yahoo Finance· 6 months agoDive Brief: Gilead Sciences is laying off about 7% of employees at cell therapy unit Kite Pharma in a restructuring it said is meant to better align the...
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of...
Benzinga via Yahoo Finance· 2 years agoThe European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta...
Gilead expands Arcellx cancer cell therapy deal
BioPharma Dive via Yahoo Finance· 6 months agoDive Brief: Gilead is expanding its collaboration with cancer cell therapy developer Arcellx, announcing Wednesday that subsidiary Kite Pharma has used...
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
Investor's Business Daily· 1 year agoRecent initial public offering Arcellx forged a $325 million multiple myeloma deal with Gilead...
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Benzinga via Yahoo Finance· 2 years agoThe U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb...
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
Reuters via Yahoo Finance· 2 years agoWASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's...
Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates
GuruFocus.com via Yahoo Finance· 6 months agoArcellx Inc (NASDAQ:ACLX) announces promising updates on CART-ddBCMA trial with median follow-up of 22 months. Financials show $482.7 million in cash reserves, funding operations into 2026.
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
Zacks via Yahoo Finance· 11 months agoArcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or...
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Investor's Business Daily· 8 months agoInvestors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said...
